Regenxbio (RGNX) said Wednesday that new interim data from two additional patients with Duchenne muscular dystrophy in a phase 1/2 study of investigational gene therapy RGX-202 added to "consistent, robust" microdystrophin and transduction levels across all treated ages.
The company said microdystrophin expression was measured at 122.3% in a 3-year-old patient and 31.5% in a 7-year-old patient compared to control.
Regenxbio said it is enrolling ambulatory patients 1 year old and older for a phase 3 trial and is on track to submit a biologics license application with the US Food and Drug Administration in mid-2026.
Shares of the company were up more than 5% in recent trading.
Price: 8.20, Change: +0.40, Percent Change: +5.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。